162 related articles for article (PubMed ID: 25966960)
1. Rituximab preserves vision in ocular mucous membrane pemphigoid.
Rübsam A; Stefaniak R; Worm M; Pleyer U
Expert Opin Biol Ther; 2015 Jul; 15(7):927-33. PubMed ID: 25966960
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
4. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).
Maley A; Warren M; Haberman I; Swerlick R; Kharod-Dholakia B; Feldman R
J Am Acad Dermatol; 2016 May; 74(5):835-40. PubMed ID: 26936298
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study.
You C; Lamba N; Lasave AF; Ma L; Diaz MH; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1221-1228. PubMed ID: 28154932
[TBL] [Abstract][Full Text] [Related]
6. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
[TBL] [Abstract][Full Text] [Related]
8. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.
Shetty S; Ahmed AR
J Am Acad Dermatol; 2013 Mar; 68(3):499-506. PubMed ID: 23200198
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of rituximab in patients with mucous membrane pemphigoid.
Amir Dastmalchi D; Moslemkhani S; Bayat M; Balighi K; Abedini R; Mahmoudi H; Daneshpazhooh M
J Dermatolog Treat; 2022 Mar; 33(2):1084-1090. PubMed ID: 32723108
[TBL] [Abstract][Full Text] [Related]
10. Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series.
Steger B; Madhusudan S; Kaye SB; Stylianides A; Romano V; Maqsood SE; Harper J; Ahmad S
Cornea; 2016 Dec; 35(12):1611-1614. PubMed ID: 27661067
[TBL] [Abstract][Full Text] [Related]
11. Disease Relapse After Drug-Free Remission in Ocular Mucous Membrane Pemphigoid.
Shifera AS; Hong GH; Khan IR; Okeagu C; Thorne JE
Am J Ophthalmol; 2021 Mar; 223():21-27. PubMed ID: 32976845
[TBL] [Abstract][Full Text] [Related]
12. Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab.
Baniel A; Oestreicher-Kedem Y; Peled A; Bar-Ilan E; Geller S; Sprecher E; Baum S
Clin Exp Dermatol; 2021 Jul; 46(5):915-919. PubMed ID: 33811681
[TBL] [Abstract][Full Text] [Related]
13. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
Foster CS; Chang PY; Ahmed AR
Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.
Saw VP; Dart JK; Rauz S; Ramsay A; Bunce C; Xing W; Maddison PG; Phillips M
Ophthalmology; 2008 Feb; 115(2):253-261.e1. PubMed ID: 17655931
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
17. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
18. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
[TBL] [Abstract][Full Text] [Related]
19. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study.
Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T
Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
